Figure 1: Circulating glucose levels. | Scientific Reports

Figure 1: Circulating glucose levels.

From: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Figure 1

(a,b) Fasted blood glucose at baseline and three days after treatment start, (c,d) fasted plasma glucose at baseline and treatment end, and (e) glycated hemoglobin at treatment end in db/m (open) and db/db (grey) mice. Circles (ο) vehicle-treated; squares (◽) empagliflozin-treated; triangles (▵) metformin-treated; and diamonds (◊) empagliflozin + metformin co-treated. Data are means ± SEM (n = 5–11). (a,c,e): *P < 0.05 vs db/m vehicle, †P < 0.05 vs db/db vehicle, δP < 0.05 vs db/db metformin within a time point by one-way ANOVA and Tukey’s post hoc. Comparisons by Student’s unpaired t-test: significance denoted by solid lines and trends denoted by dashed lines. (b,d): #P < 0.05 delta change (▵) from baseline by Student paired t-test. N.B. (a,b): Some mice exceeded the upper limit of the glucometer, in which case the recorded blood glucose value was 33.3 mmol/L. Differences from baseline may therefore be underestimated.

Back to article page